CCM
ATEX icon

Cloverdale Capital Management’s Anterix ATEX Stock Holding History

Cloverdale Capital Management’s Portfolio ATEX Stock Details ATEX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-67,636
Closed -$2.92M – 26
2019
Q4 		$2.92M Buy
+67,636
New +$2.76M 1.89% 15

Other funds holding ATEX

OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
LCM
Lomas Capital Management New York $1.04B AUM 24.59% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
FS
Feinberg Stephen $2.61B AUM 15.12% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCC
Bain Capital Credit Boston, Massachusetts $303M AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Cloverdale Capital Management's ATEX Position: Q1 2020 in Review

Cloverdale Capital Management sold out of Anterix (ATEX) in Q1 2020, closing a stake of 67,636 shares — an estimated $2.92M sold.

Cloverdale Capital Management first reported a position in ATEX in Q4 2019 and held it in 1 quarter. The position peaked at $2.92M in Q4 2019. 84 funds tracked by Wall St. Rank hold ATEX as of Q1 2020.

  • Cloverdale Capital Management reported no remaining Anterix position as of Q1 2020 after selling out during the quarter.
  • Cloverdale Capital Management sold 67,636 Anterix shares in Q1 2020, an estimated $2.92M.
  • Cloverdale Capital Management first reported a position in Anterix in Q4 2019 and held it in 1 quarter.
  • Cloverdale Capital Management's Anterix position peaked at $2.92M in Q4 2019.
  • 84 funds tracked by Wall St. Rank held Anterix as of Q1 2020.

Based on Cloverdale Capital Management's 13F filing for Q1 2020, filed 15 May 2020.